Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499723 | PMC |
| http://dx.doi.org/10.1093/qjmed/hcab214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letter to the Editor in response to Performance of the Washington Group questions in measuring blindness and deafness by Landes et al.
Health Aff Sch
January 2025
Burton Blatt Institute, Syracuse University, Syracuse, NY 13244-2130, United States.
Impaired Visuospatial Processing in Cerebral Visual Impairment Revealed by Performance on a Conjunction Visual Search Task.
Br J Vis Impair
September 2024
The Laboratory for Visual Neuroplasticity, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, USA.
Cerebral visual impairment (CVI) is a brain-based visual disorder associated with injury and/or maldevelopment of central visual pathways. Visuospatial processing impairments are a cardinal feature of the complex clinical profile of individuals with CVI. Here, we assessed visuospatial processing abilities using a classic conjunction search task.
View Article and Find Full Text PDFReal-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Biomark Res
January 2025
Incyte Corporation, Wilmington, DE, USA.
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting.
View Article and Find Full Text PDFWT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
J Hematol Oncol
January 2025
Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium.
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant vaccination with Wilms' tumor protein (WT1) mRNA-electroporated autologous dendritic cells (WT1-mRNA/DC) in a single-arm phase I/II clinical study of patients with advanced solid tumors receiving standard therapy. Disease status and immune reactivity were evaluated after 8 weeks and 6 months.
View Article and Find Full Text PDFOptimising patient engagement for assessing total joint arthroplasty outcomes - a randomised controlled trial.
J Orthop Surg Res
January 2025
Department of Orthopaedic Surgery, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Introduction: Patient satisfaction is a critical outcome in total joint arthroplasty (TJA), yet assessing it effectively remains a challenge due to limitations in patient-reported outcome measures (PROMS). While these measures are commonly gathered in clinical settings, additional contact through mail or phone is often needed, and low response rates can affect the validity and reliability of collected data. To improve response rates, this study evaluated various methods of incentivizing patient participation in a randomized trial format, focusing on postal questionnaires.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!